FPMI (FluoroPharma Medical) Debt-to-Asset : 17.39 (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Debt-to-Asset?

FluoroPharma Medical FPMI Debt-to-Asset is 17.39 as of Dec. 2016.

FluoroPharma Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was $5.83 Mil. FluoroPharma Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was $0.00 Mil. FluoroPharma Medical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2016 was $0.34 Mil. FluoroPharma Medical's debt to asset for the quarter that ended in Dec. 2016 was 17.39.

FluoroPharma Medical  (OTCPK:FPMI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

FluoroPharma Medical Debt-to-Asset Related Terms

FluoroPharma Medical Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Debt-to-Asset Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.59 5.18 17.39

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 11.02 6.96 14.56 17.39

FPMI vs HSTC, OBMPD, GOVX: Debt-to-Asset Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FluoroPharma Medical Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Debt-to-Asset falls into.


FluoroPharma Medical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

FluoroPharma Medical's Debt-to-Asset for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.825 + 0) / 0.335
=17.39

FluoroPharma Medical's Debt-to-Asset for the quarter that ended in Dec. 2016 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.825 + 0) / 0.335
=17.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 17.39 mean?
FluoroPharma Medical (FPMI) has a Debt-to-Asset of 17.39 as of Dec. 2016. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Debt-to-Asset too high?
FluoroPharma Medical's current Debt-to-Asset is 17.39.
How does FluoroPharma Medical's Debt-to-Asset compare to HSTC and OBMPD?
FluoroPharma Medical's Debt-to-Asset of 17.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on FluoroPharma Medical and its competitors. FluoroPharma Medical's current Debt-to-Asset is 17.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Debt-to-Asset of 17.39. The current Debt-to-Asset is 17.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Debt-to-Asset is 17.39 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.